Refractory Adrenal Gland Pheochromocytoma clinical trials at UCSF
1 research study open to eligible people
Refractory adrenal gland pheochromocytoma is a rare tumor that can cause high blood pressure, sweating, and anxiety. UCSF is conducting a clinical trial for this condition. The trial explores the effectiveness of a treatment called Tipifarnib for children and adults with advanced tumors that contain certain gene alterations. If you or your child has been diagnosed with this condition, you may be eligible to participate in this trial.
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
open to eligible people ages 12 months to 21 years
This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a genetic alteration in the gene HRAS. Tipifarnib may block the growth of cancer cells that have specific genetic changes in a gene called HRAS and may reduce tumor size.
Oakland, California and other locations
Our lead scientists for Refractory Adrenal Gland Pheochromocytoma research studies include Carla B. Golden Arun A. Rangaswami.
Last updated: